Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche

Bayer rejects WirtschaftsWoche report on Dicamba lawsuits

Bayer: Conditions for beginning Monsanto integration fulfilled

Legal remedies against jury verdict in California announced ...

Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases

Bayer announces acceptance of nine abstracts on the use of Xarelto® in patients from a broad range of clinical and real-world studies

New COMPASS data about bleeding and cancer risk in patients with vascular disease ...

Bayer showcases Root2Success for healthy soils and roots

Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million

Two years’ support for five social impact start-ups in healthcare and nutrition / Visionary entrepreneurs helping to improve millions of people’s lives / Grant for handheld breast cancer screening device developed in the USA and being piloted in Brazil ...

Bayer receives approval of new treatment regimen for Eylea® in the EU

New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more ...

LEO Pharma to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit

Significant step to bolster LEO Pharma’s role as a leading global dermatology company with its goal of helping 125 million patients by 2025 ...

Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease

Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events ...